Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biomx Inc PHGE

Alternate Symbol(s):  PHGEW | PHGE.U

Healthcare Biotechnology
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer... see more

Recent & Breaking News (NYSEAM:PHGE)

BiomX Announces Corporate Restructuring

Business Wire May 24, 2022

BiomX Announces Publication in the Journal, Bioinformatics

Business Wire May 20, 2022

BiomX Reports First Quarter 2022 Financial Results and Provides Business Update

Business Wire May 11, 2022

BiomX to Host Key Opinion Leader Event on BX004 for Treatment of Pseudomonas Aeruginosa Infections in Cystic Fibrosis Patients

Business Wire May 6, 2022

BiomX to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 11, 2022

Business Wire May 5, 2022

BiomX Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Business Wire March 30, 2022

BiomX to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on March 30, 2022

Business Wire March 23, 2022

BiomX Presenting at Three Upcoming Investor Conferences

Business Wire February 24, 2022

BiomX Announces Therapeutics Development Award of up to $5 Million from the Cystic Fibrosis Foundation

Business Wire January 4, 2022

BiomX Presenting at Two Upcoming Conferences in November

GlobeNewswire November 17, 2021

BiomX Reports Third Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire November 15, 2021

BiomX to Host Third Quarter 2021 Financial Results Conference Call and Webcast on November 15, 2021

GlobeNewswire November 9, 2021

BiomX Reports Topline Results of Phase 2 Cosmetic Acne Study

GlobeNewswire October 18, 2021

BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005

GlobeNewswire October 13, 2021

BiomX to Present at Upcoming September Investor Conferences

GlobeNewswire September 2, 2021

BiomX Reports Second Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire August 16, 2021

BiomX to Host Second Quarter 2021 Financial Results Conference Call and Webcast on August 16, 2021

GlobeNewswire August 12, 2021

BiomX Inc. Announces $15 Million Registered Direct Offering

GlobeNewswire July 26, 2021

BiomX Presents Preclinical Results With BX005 for Atopic Dermatitis at the Revolutionizing Atopic Dermatitis 2021 Virtual Conference and the International Conference on Phage Therapy and Bacteriophages

Business Wire June 14, 2021

BiomX to Present Preclinical Results with BX004 in Cystic Fibrosis at the 44th European Cystic Fibrosis Conference

Business Wire June 9, 2021